Following several development and licensing collaborations, Boehringer Ingelheim has acquired Saiba Animal Health to strengthen its animal health R&D pipeline, specifically in the fast-growing pet therapeutics category.  The Swiss startup specializes in the development of Virus-Like Particles-based therapeutic vaccines targeting major unmet medical needs in veterinary medicine..

经过几次开发和许可合作，勃林格殷格翰收购了Saiba Animal Health，以加强其动物健康研发渠道，特别是在快速增长的宠物治疗类别中。这家瑞士初创公司专门开发基于病毒样颗粒的治疗性疫苗，针对兽医中未满足的主要医疗需求。

Saiba Animal Health’s innovative technology platform uses a first-of-its-kind, patented therapeutic vaccine platform, designed to create an immune response, targeting chronic diseases such as allergy, inflammation and pain. The therapeutic vaccines incorporate virus-like particles (VLP) to induce the animal’s immune system.

Saiba Animal Health的创新技术平台使用同类首创的专利治疗性疫苗平台，旨在产生免疫反应，针对过敏、炎症和疼痛等慢性疾病。治疗性疫苗包含病毒样颗粒（VLP）以诱导动物的免疫系统。

They produce neutralizing antibodies against the animal’s own disease-causing proteins. This approach may result in a longer duration of action, better treatment outcomes, and increased pet owner convenience and compliance..

。这种方法可能会导致更长的行动持续时间，更好的治疗效果，并增加宠物主人的便利性和依从性。

Founded in 2013 as a spin-off from the University of Zurich, the Freienbach (Schwyz)-based startup has now been acquired by Boehringer Ingelheim, following several development and licensing collaborations. Together they advanced multiple species-specific product candidates, based on Saiba Animal Health’s technology platform, aiming to improve the management of chronic diseases in companion animals..

这家总部位于弗里恩巴赫（Schwyz）的初创公司成立于2013年，是苏黎世大学（University of Zurich）的附属公司，经过几次开发和许可合作，现已被勃林格殷格翰（Boehringer Ingelheim）收购。他们共同提出了基于Saiba Animal Health技术平台的多种物种特异性候选产品，旨在改善伴侣动物慢性病的管理。

“Our pets live longer which creates different needs for their medical care, and often without good existing treatment options”, said Eric Haaksma, Head of Global Innovation, Animal Health at Boehringer Ingelheim. “As a research-driven company, we are very excited about the potential of Saiba Animal Health’s groundbreaking technology platform, which could result in a more specific and longer-lasting therapeutic response to chronic diseases in companion animals than current approaches.”.

勃林格殷格翰全球创新、动物健康负责人埃里克·哈克斯玛（EricHaaksma）表示：“我们的宠物寿命更长，这对它们的医疗保健产生了不同的需求，而且通常没有良好的现有治疗选择。”。“作为一家以研究为导向的公司，我们对Saiba Animal Health开创性技术平台的潜力感到非常兴奋，与目前的方法相比，它可以对伴侣动物的慢性疾病产生更具体和更持久的治疗反应。”

Dr. Gary T. Jennings, CEO of Saiba Animal Health, said: “We are thrilled that our long-term partnership with Boehringer Ingelheim has evolved to this agreement. Joining forces will pave the way for a whole new class of therapeutic medicines for pets, with a true impact on the lives of animals and their owners.”(Press release/RAN).

Saiba Animal Health首席执行官加里·詹宁斯（Gary T.Jennings）博士表示：“我们很高兴与勃林格殷格翰（Boehringer Ingelheim）的长期合作关系已经发展成为这项协议。联合力量将为一类全新的宠物治疗药物铺平道路，对动物及其主人的生活产生真正的影响。”